Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Analog Devices, Inc. (ADI) vs Sanofi SA (SNY) Price & Performance

Analog Devices, Inc.Trade

Price performance (Past 24H)

Key statistics

Analog Devices, Inc. vs Sanofi SA — how do they compare? Analog Devices, Inc. trades at $384.86 (market cap $187.67B), while Sanofi SA trades at $43.57 (market cap $104.30B). The key difference: Analog Devices, Inc. is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.

ADISNY
Market Cap
$187.67B$104.30B
Sector
TechnologyHealth
52-Week High
$445.48$52.34
52-Week Low
$225.20$41.33
Enterprise Value
$192.92B$124.19B
Dividend Yield
1.14%5.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Analog Devices, Inc.

Analog Devices (ADI) trades at $384.29, up 0.1% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported Q1 2026 EPS of $3.09, exceeding expectations, and maintains strong profitability with a 26.01% net income margin. A dividend of $1.10 per share is scheduled for payment on June 16, 2026, reflecting cash flow stability.

ADI presents a favorable investment case with analyst consensus strongly bullish (79.63% buy ratings) and a price target of $472.29, implying significant upside. Risks include elevated valuation multiples (P/E of 57.34) and semiconductor cycle volatility, but robust fundamentals and AI-driven demand support long-term growth prospects.

Sanofi SA

SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.

Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Analog Devices, Inc.

Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.

Read more on ADI

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY